Observations placeholder

Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the steroid hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications.

Trade names include Provera.

MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is almost always being referred to is MPA and not MP. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

In females, the most common use of MPA is as an oral or depot-injected contraceptive and also as the progestin component of menopausal hormone replacement therapy. MPA is also used as a treatment for endometriosis, dysmenorrhea, and amenorrhea. MPA, along with other progestins were developed to allow the hormones to be taken orally, as progesterone (the hormone made by the human body) could not be taken orally before the process of micronization was developed.

In males, MPA has been used to control inappropriate sexual behavior to chemically castrate convicted sex offenders.

It has also been used to treat benign prostatic hyperplasia, as a palliative appetite stimulant for cancer patients, and at high doses (800 mg per day) to treat hormone-dependent cancers of primarily the breast, but also other types.

Women taking MPA may experience spotting shortly after starting the medication . With longer use amenorrhoea can occur as can irregular menstruation which is a major source of dissatisfaction

MPA has also been prescribed in hormone replacement therapy for male-to-female transgender individuals due to its antiandrogen and progestogen effects.

MPA acts as an agonist of the progesterone, androgen, and glucocorticoid receptors (PR, AR, and GR, respectively),

On Jul, 12, 2015: 9,736 people reported to have side effects when taking Medroxyprogesterone acetate. Among them, 4 people (0.04%) have Hallucinations.

Time on Medroxyprogesterone acetate when people have Hallucinations  :

Age of people who have Hallucinations when taking Medroxyprogesterone acetate  :

On Aug, 10, 2015: 43,964 people reported to have side effects when taking Provera. Among them, 34 people (0.08%) have Hallucinations.

Time on Provera when people have Hallucinations  :

Age of people who have Hallucinations when taking Provera  :

0-12-910-1920-2930-3940-4950-5960+ Hallucinations0.00%0.00%9.09%54.55%0.00%24.24%6.06%6.06%